Belite Bio (BLTE) Competitors

Roivant Sciences (NASDAQ:ROIV) and Belite Bio (NASDAQ:BLTE) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, community ranking, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Is ROIV or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-119.54%	-14.05%	-12.81%
Belite Bio	N/A	-31.94%	-30.73%

Does the MarketBeat Community believe in ROIV or BLTE?

Roivant Sciences received 19 more outperform votes than Belite Bio when rated by MarketBeat users. However, 97.30% of users gave Belite Bio an outperform vote while only 78.57% of users gave Roivant Sciences an outperform vote.

Company	Underperform	Outperform
Roivant Sciences	Outperform Votes 55 78.57%	Underperform Votes 15 21.43%
Belite Bio	Outperform Votes 36 97.30%	Underperform Votes 1 2.70%

Does the media prefer ROIV or BLTE?

In the previous week, Belite Bio had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 19 mentions for Belite Bio and 15 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.47 beat Belite Bio's score of 0.09 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	12 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer ROIV or BLTE?

Roivant Sciences presently has a consensus target price of $17.50, suggesting a potential upside of 60.40%. Belite Bio has a consensus target price of $96.67, suggesting a potential upside of 43.66%. Given Roivant Sciences' higher possible upside, research analysts plainly believe Roivant Sciences is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Belite Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger valuation & earnings, ROIV or BLTE?

Roivant Sciences has higher revenue and earnings than Belite Bio. Roivant Sciences is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$122.59M	63.51	$4.35B	-$0.15	-72.73
Belite Bio	N/A	N/A	-$31.63M	-$1.36	-49.48

Which has more volatility & risk, ROIV or BLTE?

Roivant Sciences has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.48, meaning that its share price is 248% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of ROIV or BLTE?

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Roivant Sciences beats Belite Bio on 11 of the 17 factors compared between the two stocks.